Momenta Pharmaceuticals Reports First Quarter 2017 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St slips on rising bond yields; Walmart results weigh
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Momenta Phama (MNTA) Tops Q2 EPS by 20c
May 2, 2017 8:02 AM EDTMomenta Phama (NASDAQ: MNTA) reported Q2 EPS of ($0.46), $0.20 better than the analyst estimate of ($0.66). Revenue for the quarter came in at $23.4 million versus the consensus estimate of $24.49 million.
Company reports Glatopa® 20 mg product revenues of $23 million, a 58% increase over the same... More